Journal of the neurological sciencesHumansCladribineMiddle AgedMaleFemale
Efficacy and safety of Cladribine as a therapeutic option in multiple sclerosis patients over 50 years of age: A real-world study.
María Agustina Piedrabuena, Jorge Correale, Berenice Silva, Marcela Fiol, Mariano Marrodan, Maria Agustina Zárate, Alejandra Heriz, Jeremías Ayerbe, Jimena Míguez, Cecilia Pita, Luciana Lázaro, Magdalena Casas, Pablo Adrián López, Verónica Tkachuk, María Eugenia Balbuena
Published: 202510.1016/j.jns.2025.123727
Abstract
BACKGROUND: Despite an aging multiple sclerosis (MS) population, clinical outcomes and long-termeffects of disease-modifying therapies in patients aged ≥50 years remain under-studied. OBJECTIVE: To compare the efficacy and safety of cladribine in rel…
Preview only. Read the full abstract at the source